Chemotherapy Induced Cardiotoxicity
Conditions
Brief summary
Chemotherapy or radiation therapy-induced cardiotoxicity are well-recognized side effects in patients with cancer. The clinical significance of cardiotoxicity is growing with increasing cancer survivor-ship. Left ventricular (LV) functional assessment is the standard of reference to diagnose chemotherapy- or radiation therapy-induced cardiotoxicity. The investigators will investigate the usefulness of T1 mapping parameters for early detection and prediction of chemotherapy-, radiation therapy-, or other therapy-induced cardiotoxicity in breast cancer patients This study aimed to achieve early detection of chemotherapy- or radiation therapy-induced cardiotoxicity using T1 mapping magnetic resonance imaging (MRI) and determine a prognostic imaging factor of chemotherapy- or radiation therapy-induced cardiotoxicity in patients treated for breast cancer.
Detailed description
Screening and follow-up cardiac magnetic resonance imaging (CMR) protocols for diagnosis of cardiotoxicity will be conducted in patients with breast cancer who have received or are planned to receive treatment for breast cancer. The protocol will include T1 and T2 mapping and cine imaging of the LV myocardium.
Interventions
OTHERCardiac magnetic resonance imaging
The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
Sponsors
Yonsei University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
17 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patient with breast cancer
Exclusion criteria
* Contraindication of MRI * Failure with informed consent * Fail to scan screening protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease in LVEF (left ventricular ejection fraction) | 1 year after CMR scanning | Decrease in LVEF : more than 10% compared to the baseline LVEF) or LVEF \< 50% |
Secondary
| Measure | Time frame |
|---|---|
| MACE (Major adverse cardiac events) | 1 year after CMR scanning |
Countries
South Korea
Outcome results
None listed